Cinnamon May Reduce Glucose, Lipid and Cholesterol Level in Type 2 Diabetic Individuals

Cinnamon Use in Type 2 Diabetes: An Updated Systematic Review and Meta-Analysis

“…Consumption of 1 to 1.2 g/d was associated with an increase in fasting plasma glucose levels, 10,14 and hemoglobin A 1c levels 9,10 ; however, others have reported reductions in glycemic parameters at doses between 1 to 6 g/d 6-9,12,13 and in hemoglobin A 1c . [6][7][8][9][11][12][13] The same conflict occurs in lipid parameters, at 1 g/d total cholesterol, 10 LDL-C, 7,12 and triglyceride 10 levels were reported to increase, while HDL-C levels decreased. [7][8][9] Only 1 trial identified statistically significant increases in hemoglobin A 1c and fasting plasma glucose levels; however, this trial was published only as a research brief, so many of the study characteristics were unclear.…”

“…5 Several randomized controlled trials (RCTs) in humans have been conducted to explore cinnamon's efficacy; however, they report conflicting results. [6][7][8][9][10][11][12][13][14][15] A meta-analysis we conducted previously did not show any statistically significant effect on glucose or lipid parameters 16 ; since that time, additional RCTs have been published investigating this effect. [11][12][13][14][15] To update our prior systematic review and meta-analysis, we added the newly published evidence to determine the effect of cinnamon in patients with type 2 diabetes on glycemic and serum lipid levels.…”

“…[6][7][8][9][10][11][12][13][14][15] A number of trials required concomitant oral hyperglycemic agent therapy. 6,7,9,11,15 A total of 8 trials reported usable data for hemoglobin A 1c levels [7][8][9][10][11][12]14,15 ; 9 trials reported results for fasting plasma glucose levels [6][7][8][9][10][12][13][14][15] ; 9 trials reported results for total cholesterol levels, [6][7][8][9][10][12][13][14][15] 8 for LDL-C levels, 6,7,9,10,12-15 8 for HDL-C levels, 7-10,12-15 and 9 for triglyceride levels. [6][7][8][9][10][12][13][14][15] Patients wer...…”

“…6,10,12 One trial evaluated C cassia that was in a combination form with zinc gluconate and tricalcium phosphate, 14 and 1 trial evaluated C aromaticum, 15 whereas the 2 remaining trials did not specify the type of cinnamon evaluated. 7,13 All trials specified administration of cinnamon with relation to food, with 1 trial specifying cinnamon be taken before meals, 15 2 trials after meals, 6,13 and the remaining trials with meals. [7][8][9][10][11][12]14 One trial had no losses to followup, and all patients were accounted for in the analysis 8 ; 2 trials specified that they conducted an intentionto-treat analysis of their data, 10,11 but 1 did not report the number of patients lost to follow-up 10 ; 2 trials excluded the patients who withdrew from the study in their analysis 7,15 ; and the remaining trials did not report patient disposition or whether intention-to-treat analysis was conducted.…”

“…[7][8][9][10][11][12]14 One trial had no losses to followup, and all patients were accounted for in the analysis 8 ; 2 trials specified that they conducted an intentionto-treat analysis of their data, 10,11 but 1 did not report the number of patients lost to follow-up 10 ; 2 trials excluded the patients who withdrew from the study in their analysis 7,15 ; and the remaining trials did not report patient disposition or whether intention-to-treat analysis was conducted. 6,9,13,14 The risk of bias assessment for individual validity components is presented in Supplemental Figure 1, available at http://annfammed. org/content/11/5/452/suppl/DC1.…”